Dr. Yasir B. Al-Wakeel BCh, BM, MA Net Worth

The estimated Net Worth of Yasir B. Al Wakeel is at least $786 Thousand dollars as of 6 July 2023. Dr Wakeel owns over 9,617 units of Kronos Bio stock worth over $332,223 and over the last 9 years he sold KRON stock worth over $32,535. In addition, he makes $421,257 as CFO & Head of Corp. Devel. at Kronos Bio.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Dr MA KRON stock SEC Form 4 insiders trading

Dr has made over 4 trades of the Kronos Bio stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 9,617 units of KRON stock worth $16,830 on 6 July 2023.

The largest trade he's ever made was exercising 17,241 units of Kronos Bio stock on 17 July 2018 worth over $99,998. On average, Dr trades about 2,420 units every 107 days since 2015. As of 6 July 2023 he still owns at least 346,102 units of Kronos Bio stock.

You can see the complete history of Dr Wakeel stock trades at the bottom of the page.

Dr. Yasir B. Al-Wakeel BCh, BM, MA biography

Dr. Yasir B. Al-Wakeel BCh, BM, MA is the CFO & Head of Corp. Devel. at Kronos Bio.

What is the salary of Dr MA?

As the CFO & Head of Corp. Devel. of Kronos Bio, the total compensation of Dr MA at Kronos Bio is $421,257. There are 2 executives at Kronos Bio getting paid more, with Jorge F. DiMartino M.D., Ph.D. having the highest compensation of $765,105.

How old is Dr MA?

Dr MA is 39, he's been the CFO & Head of Corp. Devel. of Kronos Bio since . There are 9 older and 1 younger executives at Kronos Bio. The oldest executive at Kronos Bio, Inc. is Dr. Norbert W. Bischofberger Ph.D., 65, who is the Pres, CEO & Director.

What's Dr MA's mailing address?

Yasir's mailing address filed with the SEC is C/O KRONOS BIO, INC., 1300 SO. EL CAMINO REAL, SUITE 400, SAN MATEO, CA, 94402.

Insiders trading at Kronos Bio

Over the last 4 years, insiders at Kronos Bio have traded over $6,434,800 worth of Kronos Bio stock and bought 7,151,111 units worth $30,320,233 . The most active insiders traders include John C Martin, Norbert W Bischofberger, and Arie Belldegrun. On average, Kronos Bio executives and independent directors trade stock every 33 days with the average trade being worth of $178,391. The most recent stock trade was executed by Norbert W Bischofberger on 27 June 2024, trading 615,518 units of KRON stock currently worth $732,466.

What does Kronos Bio do?

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Complete history of Dr Wakeel stock trades at Merrimack Pharmaceuticals Inc and Kronos Bio

Kronos Bio executives and stock owners

Kronos Bio executives and other stock owners filed with the SEC include:

• Jorge F. DiMartino M.D., Ph.D.,
  Chief Medical Officer & Exec. VP of Clinical Devel.
• Dr. Norbert W. Bischofberger Ph.D.,
  Pres, CEO & Director
• Dr. Yasir B. Al-Wakeel BCh, BM, MA,
  CFO & Head of Corp. Devel.
• Dr. Norbert W. Bischofberger,
  Pres, CEO & Director
• David M. Tanen J.D.,
  Sec. & Director
• Joshua A. Kazam,
  Co-Founder & Director
• Marni Kottle,
  Sr. VP of Corp. Communications & Investor Relations
• Dr. Christopher Dinsmore Ph.D.,
  Chief Scientific Officer
• Barbara A. Kosacz J.D.,
  COO & Gen. Counsel
• Charles Lin Ph.D.,
  Sr. VP of Biology
• Dr. Pasit Phiasivongsa Ph.D.,
  Sr. VP of Pharmaceutical Devel.
• Stephanie Yao,
  Exec. Director of Investor Relations & Corp. Communications
• Dr. Christopher Dinsmore,
  Chief Scientific Officer
• Barbara A. Kosacz,
  COO & Gen. Counsel
• Dr. Yasir B. Al-Wakeel,
  CFO & Head of Corp. Devel.
• Norbert W Bischofberger,
  PRESIDENT & CEO
• Barbara Kosacz,
  COO & General Counsel
• Yasir B. Al Wakeel,
  Chief Financial Officer
• Christopher Dinsmore,
  Chief Scientific Officer
• Norbert W. & Inger A. Revoc...,
  10% owner
• Arie Belldegrun,
  
• Rebecka Belldegrun,
  Director
• Jakob Loven,
  Director
• John C Martin,
  Director
• Otello Stampacchia,
  Director
• Fund V, L.P.Omega Fund V Gp...,
  
• Jorge Di Martino,
  Chief Medical Officer & VP
• Backer Marianne De,
  Director
• Roshawn A. Blunt,
  
• Roger D Dansey,
  
• David M Tanen,
  
• Joshua A Kazam,
  
• Allison Frisbee,
  SR VP, CORP OPERATIONS & LEGAL
• Charles Y Lin,
  SR VP, RESEARCH & DEVELOPMENT
• Elizabeth A Olek,
  SR VP, CLINICAL SCIENCE
• Taiyin Yang,
  
• Elena Ridloff,
  
• Katherine V Stultz,
  
• Deborah Knobelman,
  Chief Financial Officer